Literature DB >> 10204154

Prostate cancer risk assessment program. A model for the early detection of prostate cancer.

D W Bruner1, A Baffoe-Bonnie, S Miller, M Diefenbach, J V Tricoli, M Daly, W Pinover, S C Grumet, J Stofey, E Ross, S Raysor, A Balshem, J Malick, P Engstrom, G E Hanks, I Mirchandani.   

Abstract

Prostate cancer is the most common form of cancer (except skin cancer) in men. Several factors have been associated with an increased risk for prostate cancer, including age, ethnicity, family history, lifestyle, and environmental exposures. Recognition of the importance of the interaction of these factors in prostate cancer has led to an interest in their evaluation as a model both for studying genetic susceptibility patterns and for studying and providing educational tools and preventive interventions. One such model has been developed at Fox Chase Cancer Center. Critical to the implementation of the model has been the establishment of the Prostate Cancer Risk Registry (PCRR) and Prostate Cancer Risk Assessment Program (PRAP). Together, they serve as a unique resource for investigating the interaction between environmental factors and genetic susceptibility patterns; exploring the early, premalignant biological markers of prostate cancer; and prospectively assessing the quality of life (QOL) of men at risk. In addition, PRAP facilitates the evaluation of models for prostate cancer risk counseling and screening in the community. This paper describes this model for early detection and risk reduction, along with preliminary data from its first two study aims. The program is particularly relevant in view of the wealth of genetic information emerging from the Human Genome Project.

Entities:  

Mesh:

Year:  1999        PMID: 10204154

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  11 in total

1.  Psychological and screening profiles of first-degree relatives of prostate cancer patients.

Authors:  S M Miller; M A Diefenbach; L K Kruus; D Watkins-Bruner; G E Hanks; P F Engstrom
Journal:  J Behav Med       Date:  2001-06

2.  Rates and predictors of colorectal cancer screening by race among motivated men participating in a Prostate Cancer Risk Assessment Program.

Authors:  Michael J Hall; Karen Ruth; Veda N Giri
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

3.  Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val.

Authors:  Veda N Giri; Karen Ruth; Lucinda Hughes; Robert G Uzzo; David Y T Chen; Stephen A Boorjian; Rosalia Viterbo; Timothy R Rebbeck
Journal:  BJU Int       Date:  2010-08-24       Impact factor: 5.588

4.  Systematic biochemical analysis of somatic missense mutations in DNA polymerase β found in prostate cancer reveal alteration of enzymatic function.

Authors:  Chang Long An; Desheng Chen; Nick M Makridakis
Journal:  Hum Mutat       Date:  2011-03-01       Impact factor: 4.878

5.  Substantial family history of prostate cancer in black men recruited for prostate cancer screening: results from the Prostate Cancer Risk Assessment Program.

Authors:  Kathleen Mastalski; Elliot J Coups; Karen Ruth; Susan Raysor; Veda N Giri
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

6.  Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer.

Authors:  Marilyn Tseng; Veda Giri; Deborah Watkins-Bruner; Edward Giovannucci
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

7.  Prostate cancer early detection program recruitment methods and show rates in men at high risk.

Authors:  Veda N Giri; Elliot J Coups; Karen Ruth; Julia Goplerud; Susan Raysor; Taylor Y Kim; Loretta Bagden; Kathleen Mastalski; Debra Zakrzewski; Suzanne Leimkuhler; Deborah Watkins-Bruner
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

8.  Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men.

Authors:  Veda N Giri; Brian Egleston; Karen Ruth; Robert G Uzzo; David Y T Chen; Mark Buyyounouski; Susan Raysor; Stanley Hooker; Jada Benn Torres; Teniel Ramike; Kathleen Mastalski; Taylor Y Kim; Rick Kittles
Journal:  Cancer Prev Res (Phila)       Date:  2009-02-24

9.  Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities.

Authors:  Salimah H Meghani; Christopher S Lee; Alexandra L Hanlon; Deborah W Bruner
Journal:  BMC Med Inform Decis Mak       Date:  2009-11-27       Impact factor: 2.796

10.  Prevalence and correlates of vitamin D status in African American men.

Authors:  Marilyn Tseng; Veda Giri; Deborah W Bruner; Edward Giovannucci
Journal:  BMC Public Health       Date:  2009-06-18       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.